Oslo, August 06, 2024. Lytix Biopharma announces that its licensing partner,
Verrica Pharmaceuticals, will host an investor call to report preliminary
top-line data of its phase II study in patients with the skin cancer disease
basal cell carcinoma on Wednesday, August 14 at 14:30 CET (included in Verrica's
presentation of its second quarter financial results). 

In this phase II study, Lytix's lead drug candidate LTX-315 (named VP-315 in
Verrica's study) has been tested in basal cell carcinoma patients. BCC is the
most common type of cancer worldwide, with 3-4 million annual incidents in the
US alone, and the global market is estimated to be USD 11.5 billion annually
within 2028.  

"We're very excited for the coming topline results from Verrica. Skin cancer is
one of the largest cancer indications worldwide and still growing. We strongly
believe that our oncolytic molecules have the potential to contribute to the
treatment of several cancer indications in the future", says CEO Dr. Øystein
Rekdal.

Lytix will update the market shortly following the announcement from Verrica,
and will hold a webcast on Thursday, August 15 at 11:00 CET (link will be
accessible through Overview - Lytix Biopharma and included in a stock release on
the publication date). 

You can read the detailed press release from Verrica here:
https://verrica.com/press_release/verrica-pharmaceuticals-to-report-second-quart
er-financial-results-and-release-preliminary-topline-results-from-part-2-of-phas
e-2-trial-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-on-august-14/  

Sign up to the presentation by Verrica on this link:
https://viavid.webcasts.com/starthere.jsp?ei=1678543&tp_key=8db298d3d3  

In addition to Verrica's study in patients with BCC, Lytix has an ongoing study
(ATLAS-IT-05) in late-stage skin melanoma patients and is starting another study
in early-stage melanoma patients this summer at Oslo University Hospital
(Radiumhospitalet). 

For more information, please contact: 
Dr. Øystein Rekdal, CEO 
oystein.rekdal@lytixbiopharma.com
+47 975 73 358

Gjest Breistein, CFO 
gjest.breistein@lytixbiopharma.com 
+47 952 60 512

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly novel technology based on world-leading research in host-defense
peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a
first-in-class oncolytic molecule representing a new principle to boost
anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work
in many different cancer indications and treatment settings, both as mono- and
combination therapy.

About Verrica Pharmaceuticals
Verrica is a dermatology therapeutics company developing medications for skin
diseases requiring medical interventions. On July 21, 2023, YCANTH®
(cantharidin), became the first treatment approved by the FDA to treat adult and
pediatric patients two years of age and older with molluscum contagiosum, a
highly contagious viral skin infection affecting approximately 6 million people
in the United States, primarily children. YCANTH (VP-102) is also in development
to treat common warts and external genital warts, two of the largest remaining
unmet needs in medical dermatology. Verrica is also developing VP-103, its
second cantharidin-based product candidate, for the treatment of plantar warts.
Verrica has also entered a worldwide license agreement with Lytix Biopharma AS
to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for
non-melanoma skin cancers including basal cell carcinoma and squamous cell
carcinoma. For more information, visit www.verrica.com.